These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20012671)

  • 1. Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity.
    Chang L; Zhou C; Xu M; Liu J
    J Comput Aided Mol Des; 2010 Jan; 24(1):37-47. PubMed ID: 20012671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
    Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
    Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris.
    Hu S; Li L; Qiao J; Guo Y; Cheng L; Liu J
    Protein Expr Purif; 2006 May; 47(1):249-57. PubMed ID: 16403645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies.
    Wang JN; Feng JN; Yu M; Xu M; Shi M; Zhou T; Yu XD; Shen BF; Guo N
    Mol Immunol; 2004 Feb; 40(13):963-9. PubMed ID: 14725792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
    Neve RM; Nielsen UB; Kirpotin DB; Poul MA; Marks JD; Benz CC
    Biochem Biophys Res Commun; 2001 Jan; 280(1):274-9. PubMed ID: 11162510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.
    Franklin MC; Carey KD; Vajdos FF; Leahy DJ; de Vos AM; Sliwkowski MX
    Cancer Cell; 2004 Apr; 5(4):317-28. PubMed ID: 15093539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel ErbB2 epitope targeted by human antitumor immunoagents.
    Troise F; Monti M; Merlino A; Cozzolino F; Fedele C; Russo Krauss I; Sica F; Pucci P; D'Alessio G; De Lorenzo C
    FEBS J; 2011 Apr; 278(7):1156-66. PubMed ID: 21288302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity-matured antibody with a disulfide bond in H-CDR3 loop.
    Yoshida M; Hanazono Y; Numoto N; Nagao S; Yabuno S; Kitagawa Y; Sekiguchi H; Ito N; Azuma T; Oda M
    Arch Biochem Biophys; 2024 Aug; 758():110068. PubMed ID: 38909835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering.
    Thakkar S; Nanaware-Kharade N; Celikel R; Peterson EC; Varughese KI
    Sci Rep; 2014 Jan; 4():3673. PubMed ID: 24419156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
    Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
    Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformational flexibility of the ErbB2 ectodomain and trastuzumab antibody complex as revealed by molecular dynamics and principal component analysis.
    Franco-Gonzalez JF; Cruz VL; Ramos J; Martínez-Salazar J
    J Mol Model; 2013 Mar; 19(3):1227-36. PubMed ID: 23160933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
    Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
    Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure.
    Wang J; Feng J; Shi M; Qian L; Chen L; Yu M; Xu R; Shen B; Guo N
    Mol Immunol; 2008 Jan; 45(1):106-16. PubMed ID: 17572496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
    Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G
    Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes.
    Deng X; Zheng X; Yang H; Moreira JM; Brünner N; Christensen H
    PLoS One; 2014; 9(9):e106448. PubMed ID: 25192037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification and characterization of a single-chain chimeric anti-p185 antibody expressed by CHO-GS system.
    Wang J; Shi Y; Liu Y; Hu S; Ma J; Liu J; Cheng L
    Protein Expr Purif; 2005 May; 41(1):68-76. PubMed ID: 15802223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity.
    Cao Y; Marks JD; Huang Q; Rudnick SI; Xiong C; Hittelman WN; Wen X; Marks JW; Cheung LH; Boland K; Li C; Adams GP; Rosenblum MG
    Mol Cancer Ther; 2012 Jan; 11(1):143-53. PubMed ID: 22090420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
    Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD
    J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.